|Bid||1.8500 x 1100|
|Ask||1.9000 x 3200|
|Day's range||1.8500 - 2.0000|
|52-week range||1.5050 - 7.5300|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.14|
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held...
With me today are Dr. Sean McCarthy, CytomX's chief executive offices and chairman; Amy Peterson, president and chief operating officer; and Carlos Campoy, chief financial officer. Please note that during today's call, we will be making forward-looking statements.
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?